Javascript must be enabled to continue!
Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy
View through CrossRef
AbstractBackgroundSplenectomy is an effective treatment for chronic immune thrombocytopenia (ITP); however, patients' willingness to accept splenectomy is variable.ObjectiveTo explore why some ITP patients accepted splenectomy when recommended by their physician while others refused.DesignQualitative descriptive study using one‐to‐one, in‐depth patient interviews and a team‐based approach to thematic analysis.ResultsOf 25 patients interviewed, 15 refused splenectomy and 10 accepted and were awaiting surgery. Themes about the influences on splenectomy decision making that emerged from patient interviews were (i) the perceived impact of ITP on quality of life, (ii) patients' view of splenectomy as a last resort treatment, (iii) patients' interpretations of the rates of treatment success and failure and (iv) a perceived lack of familiarity about ITP. Patients who accepted splenectomy perceived their disease as having a negative impact on their quality of life, whereas patients who refused felt their situation was not severe enough to warrant surgery. Patients developed their own experiential interpretations of the success rates of splenectomy quoted to them. A general lack of awareness of the clinical impact of ITP and its cause was identified by patients as barriers to choosing splenectomy.ConclusionsPatients' disease experience, perceptions of the lack of treatment alternatives, interpretations of treatment success and failure rates and a general lack of awareness about ITP influenced treatment choice. This study represents a first step towards contextualizing treatment decision making in ITP, focusing on patient preferences and values.
Title: Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy
Description:
AbstractBackgroundSplenectomy is an effective treatment for chronic immune thrombocytopenia (ITP); however, patients' willingness to accept splenectomy is variable.
ObjectiveTo explore why some ITP patients accepted splenectomy when recommended by their physician while others refused.
DesignQualitative descriptive study using one‐to‐one, in‐depth patient interviews and a team‐based approach to thematic analysis.
ResultsOf 25 patients interviewed, 15 refused splenectomy and 10 accepted and were awaiting surgery.
Themes about the influences on splenectomy decision making that emerged from patient interviews were (i) the perceived impact of ITP on quality of life, (ii) patients' view of splenectomy as a last resort treatment, (iii) patients' interpretations of the rates of treatment success and failure and (iv) a perceived lack of familiarity about ITP.
Patients who accepted splenectomy perceived their disease as having a negative impact on their quality of life, whereas patients who refused felt their situation was not severe enough to warrant surgery.
Patients developed their own experiential interpretations of the success rates of splenectomy quoted to them.
A general lack of awareness of the clinical impact of ITP and its cause was identified by patients as barriers to choosing splenectomy.
ConclusionsPatients' disease experience, perceptions of the lack of treatment alternatives, interpretations of treatment success and failure rates and a general lack of awareness about ITP influenced treatment choice.
This study represents a first step towards contextualizing treatment decision making in ITP, focusing on patient preferences and values.
Related Results
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Abstract
Introduction
Given pregnancy's significant impact on hematological parameters, monitoring these changes across trimesters is crucial. This study aims to evaluate hematolog...
Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study
Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study
Abstract
Abstract 392
Introduction
Primary immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder...
Splenectomy Does Not Improve Survival in Chronic Active Epstein-Barr Virus Disease Patients
Splenectomy Does Not Improve Survival in Chronic Active Epstein-Barr Virus Disease Patients
Abstract
Purpose
We aimed to evaluate the clinical value of splenectomy as a treatment for Chronic active Epstein-Barr virus disease (CAEBVD).
Methods
We retrospectively r...
Immature platelet fraction as a useful predictor of the aetiology of thrombocytopenia: experience from Oman
Immature platelet fraction as a useful predictor of the aetiology of thrombocytopenia: experience from Oman
Abstract
Clinical evaluation of the possible aetiology of thrombocytopenia is important in the management of thrombocytopenia, which is concomitant with different disease...
Frequency of Thrombocytopenia in Malaria and its prognostic significance
Frequency of Thrombocytopenia in Malaria and its prognostic significance
BACKGROUND & OBJECTIVE: Thrombocytopenia is a common hematological manifestation of malaria, but locally there is limited data on the association of thrombocytopenia degree and...
Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-Hodgkin's lymphoma
Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-Hodgkin's lymphoma
Abstract
Between 1 January 1980 and 31 July 1988, 62 patients with chronic lymphocytic leukaemia (CLL) or malignant non-Hodgkin's lymphoma (NHL) were splenectomized ...
Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
Abstract
Background
Severe neonatal thrombocytopenia is a rare disease with multiple etiologies. Severe thrombocytopenia with bleeding is life-threa...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

